ID   FAK2_HUMAN              Reviewed;        1009 AA.
AC   Q14289; D3DST0; Q13475; Q14290; Q16709; Q6PID4;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   10-MAY-2017, entry version 198.
DE   RecName: Full=Protein-tyrosine kinase 2-beta;
DE            EC=2.7.10.2;
DE   AltName: Full=Calcium-dependent tyrosine kinase;
DE            Short=CADTK;
DE   AltName: Full=Calcium-regulated non-receptor proline-rich tyrosine kinase;
DE   AltName: Full=Cell adhesion kinase beta;
DE            Short=CAK-beta;
DE            Short=CAKB;
DE   AltName: Full=Focal adhesion kinase 2;
DE            Short=FADK 2;
DE   AltName: Full=Proline-rich tyrosine kinase 2;
DE   AltName: Full=Related adhesion focal tyrosine kinase;
DE            Short=RAFTK;
GN   Name=PTK2B; Synonyms=FAK2, PYK2, RAFTK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION IN REGULATION OF
RP   POTASSIUM CHANNELS; PHOSPHORYLATION OF KCNA2 AND SHC1 AND ACTIVATION
RP   OF MAPK1/ERK2, INTERACTION WITH GRB2, AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=7544443; DOI=10.1038/376737a0;
RA   Lev S., Moreno H., Martinez R., Canoll P., Peles E., Musacchio J.M.,
RA   Plowman G.D., Rudy B., Schlessinger J.;
RT   "Protein tyrosine kinase PYK2 involved in Ca(2+)-induced regulation of
RT   ion channel and MAP kinase functions.";
RL   Nature 376:737-745(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Hippocampus;
RX   PubMed=8838818; DOI=10.1006/geno.1996.0149;
RA   Herzog H., Nicholl J., Hort Y.J., Sutherland G.R., Shine J.;
RT   "Molecular cloning and assignment of FAK2, a novel human focal
RT   adhesion kinase, to 8p11.2-p22 by nonisotopic in situ hybridization.";
RL   Genomics 32:484-486(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Hippocampus;
RX   PubMed=7673154; DOI=10.1074/jbc.270.36.21206;
RA   Sasaki H., Nagura K., Ishino M., Tobioka H., Kotani K., Sasaki T.;
RT   "Cloning and characterization of cell adhesion kinase beta, a novel
RT   protein-tyrosine kinase of the focal adhesion kinase subfamily.";
RL   J. Biol. Chem. 270:21206-21219(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=7499242; DOI=10.1074/jbc.270.46.27742;
RA   Avraham S., London R., Fu Y., Ota S., Hiregowdara D., Li J., Jiang S.,
RA   Pasztor L.M., White R.A., Groopman J.E., Avraham H.;
RT   "Identification and characterization of a novel related adhesion focal
RT   tyrosine kinase (RAFTK) from megakaryocytes and brain.";
RL   J. Biol. Chem. 270:27742-27751(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), PHOSPHORYLATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Monocyte;
RX   PubMed=9545257; DOI=10.1074/jbc.273.16.9361;
RA   Li X., Hunter D., Morris J., Haskill J.S., Earp H.S.;
RT   "A calcium-dependent tyrosine kinase splice variant in human
RT   monocytes. Activation by a two-stage process involving adherence and a
RT   subsequent intracellular signal.";
RL   J. Biol. Chem. 273:9361-9364(1998).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   FUNCTION IN PHOSPHORYLATION OF SRC AND ACTIVATION OF THE MAP KINASE
RP   SIGNALING CASCADE, INTERACTION WITH SRC, AUTOPHOSPHORYLATION, AND
RP   MUTAGENESIS OF TYR-402.
RX   PubMed=8849729; DOI=10.1038/383547a0;
RA   Dikic I., Tokiwa G., Lev S., Courtneidge S.A., Schlessinger J.;
RT   "A role for Pyk2 and Src in linking G-protein-coupled receptors with
RT   MAP kinase activation.";
RL   Nature 383:547-550(1996).
RN   [10]
RP   FUNCTION IN TNF SIGNALING AND ACTIVATION OF MAPK8/JNK1.
RX   PubMed=8670418; DOI=10.1126/science.273.5276.792;
RA   Tokiwa G., Dikic I., Lev S., Schlessinger J.;
RT   "Activation of Pyk2 by stress signals and coupling with JNK signaling
RT   pathway.";
RL   Science 273:792-794(1996).
RN   [11]
RP   INTERACTION WITH TGFB1I1.
RX   PubMed=9422762; DOI=10.1074/jbc.273.2.1003;
RA   Matsuya M., Sasaki H., Aoto H., Mitaka T., Nagura K., Ohba T.,
RA   Ishino M., Takahashi S., Suzuki R., Sasaki T.;
RT   "Cell adhesion kinase beta forms a complex with a new member, Hic-5,
RT   of proteins localized at focal adhesions.";
RL   J. Biol. Chem. 273:1003-1014(1998).
RN   [12]
RP   INTERACTION WITH ASAP2, AND FUNCTION.
RX   PubMed=10022920; DOI=10.1128/MCB.19.3.2338;
RA   Andreev J., Simon J.-P., Sabatini D.D., Kam J., Plowman G.,
RA   Randazzo P.A., Schlessinger J.;
RT   "Identification of a new Pyk2 target protein with Arf-GAP activity.";
RL   Mol. Cell. Biol. 19:2338-2350(1999).
RN   [13]
RP   INTERACTION WITH RB1CC1.
RX   PubMed=10769033; DOI=10.1083/jcb.149.2.423;
RA   Ueda H., Abbi S., Zheng C., Guan J.-L.;
RT   "Suppression of Pyk2 kinase and cellular activities by FIP200.";
RL   J. Cell Biol. 149:423-430(2000).
RN   [14]
RP   PHOSPHORYLATION AT TYR-402, MUTAGENESIS OF PRO-859, AND INTERACTION
RP   WITH NPHP1.
RX   PubMed=11493697; DOI=10.1073/pnas.171269898;
RA   Benzing T., Gerke P., Hoepker K., Hildebrandt F., Kim E., Walz G.;
RT   "Nephrocystin interacts with Pyk2, p130(Cas), and tensin and triggers
RT   phosphorylation of Pyk2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:9784-9789(2001).
RN   [15]
RP   FUNCTION IN ASAP1 PHOSPHORYLATION AND REGULATION OF ASAP1 ACTIVITY,
RP   AND INTERACTION WITH ASAP1.
RX   PubMed=12771146; DOI=10.1074/jbc.M302278200;
RA   Kruljac-Letunic A., Moelleken J., Kallin A., Wieland F., Blaukat A.;
RT   "The tyrosine kinase Pyk2 regulates Arf1 activity by phosphorylation
RT   and inhibition of the Arf-GTPase-activating protein ASAP1.";
RL   J. Biol. Chem. 278:29560-29570(2003).
RN   [16]
RP   INTERACTION WITH SKAP2, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=12893833; DOI=10.1074/jbc.M213217200;
RA   Takahashi T., Yamashita H., Nagano Y., Nakamura T., Ohmori H.,
RA   Avraham H., Avraham S., Yasuda M., Matsumoto M.;
RT   "Identification and characterization of a novel Pyk2/related adhesion
RT   focal tyrosine kinase-associated protein that inhibits alpha-synuclein
RT   phosphorylation.";
RL   J. Biol. Chem. 278:42225-42233(2003).
RN   [17]
RP   FUNCTION, INTERACTION WITH PDPK1, AND SUBCELLULAR LOCATION.
RX   PubMed=14585963; DOI=10.1128/MCB.23.22.8019-8029.2003;
RA   Taniyama Y., Weber D.S., Rocic P., Hilenski L., Akers M.L., Park J.,
RA   Hemmings B.A., Alexander R.W., Griendling K.K.;
RT   "Pyk2- and Src-dependent tyrosine phosphorylation of PDK1 regulates
RT   focal adhesions.";
RL   Mol. Cell. Biol. 23:8019-8029(2003).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=12522270; DOI=10.1073/pnas.2436191100;
RA   Salomon A.R., Ficarro S.B., Brill L.M., Brinker A., Phung Q.T.,
RA   Ericson C., Sauer K., Brock A., Horn D.M., Schultz P.G., Peters E.C.;
RT   "Profiling of tyrosine phosphorylation pathways in human cells using
RT   mass spectrometry.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:443-448(2003).
RN   [19]
RP   FUNCTION IN INTEGRIN SIGNALING AND IN REGULATION OF CELL
RP   PROLIFERATION, CATALYTIC ACTIVITY, AND CHARACTERIZATION OF ISOFORM 2.
RX   PubMed=15050747; DOI=10.1016/j.exphem.2004.01.001;
RA   Dylla S.J., Deyle D.R., Theunissen K., Padurean A.M., Verfaillie C.M.;
RT   "Integrin engagement-induced inhibition of human myelopoiesis is
RT   mediated by proline-rich tyrosine kinase 2 gene products.";
RL   Exp. Hematol. 32:365-374(2004).
RN   [20]
RP   PHOSPHORYLATION AT TYR-402, CATALYTIC ACTIVITY, FUNCTION IN
RP   SRC-MEDIATED PHOSPHORYLATION OF PXN, AND MUTAGENESIS OF LYS-457.
RX   PubMed=15166227; DOI=10.1074/jbc.M313527200;
RA   Park S.Y., Avraham H.K., Avraham S.;
RT   "RAFTK/Pyk2 activation is mediated by trans-acting autophosphorylation
RT   in a Src-independent manner.";
RL   J. Biol. Chem. 279:33315-33322(2004).
RN   [21]
RP   INTERACTION WITH LPXN AND PTPN12, PHOSPHORYLATION AT TYR-402, AND
RP   DEPHOSPHORYLATION BY PTPN12.
RX   PubMed=17329398; DOI=10.1152/ajpcell.00503.2006;
RA   Sahu S.N., Nunez S., Bai G., Gupta A.;
RT   "Interaction of Pyk2 and PTP-PEST with leupaxin in prostate cancer
RT   cells.";
RL   Am. J. Physiol. 292:C2288-C2296(2007).
RN   [22]
RP   FUNCTION IN MIGRATION OF T-LYMPHOCYTES, AND INTERACTION WITH EPHA1;
RP   LCK AND PI3-KINASE.
RX   PubMed=17634955; DOI=10.1002/eji.200737111;
RA   Hjorthaug H.S., Aasheim H.C.;
RT   "Ephrin-A1 stimulates migration of CD8+CCR7+ T lymphocytes.";
RL   Eur. J. Immunol. 37:2326-2336(2007).
RN   [23]
RP   CATALYTIC ACTIVITY, ENZYME REGULATION, AND ROLE IN DISEASE.
RX   PubMed=18339875; DOI=10.1158/0008-5472.CAN-07-5155;
RA   Roberts W.G., Ung E., Whalen P., Cooper B., Hulford C., Autry C.,
RA   Richter D., Emerson E., Lin J., Kath J., Coleman K., Yao L.,
RA   Martinez-Alsina L., Lorenzen M., Berliner M., Luzzio M., Patel N.,
RA   Schmitt E., LaGreca S., Jani J., Wessel M., Marr E., Griffor M.,
RA   Vajdos F.;
RT   "Antitumor activity and pharmacology of a selective focal adhesion
RT   kinase inhibitor, PF-562,271.";
RL   Cancer Res. 68:1935-1944(2008).
RN   [24]
RP   FUNCTION IN CELL ADHESION; MIGRATION; PROLIFERATION; REGULATION OF
RP   ACTIN FIBER POLYMERIZATION AND IN ACTIVATION OF SRC; MAPK1/ERK2 AND
RP   MAPK3/ERK1, INTERACTION WITH SRC, SUBCELLULAR LOCATION, AND ROLE IN
RP   DISEASE.
RX   PubMed=18765415; DOI=10.1093/carcin/bgn203;
RA   Sun C.K., Man K., Ng K.T., Ho J.W., Lim Z.X., Cheng Q., Lo C.M.,
RA   Poon R.T., Fan S.T.;
RT   "Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and
RT   invasiveness of hepatocellular carcinoma cells through c-Src/ERK
RT   activation.";
RL   Carcinogenesis 29:2096-2105(2008).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-375, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-375; THR-765; SER-839
RP   AND THR-842, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [27]
RP   INTERACTION WITH RHOU, AND FUNCTION IN REORGANIZATION OF ACTIN
RP   CYTOSKELETON AND SRC-MEDIATED RHOU PHOSPHORYLATION.
RX   PubMed=18086875; DOI=10.1128/MCB.00201-07;
RA   Ruusala A., Aspenstrom P.;
RT   "The atypical Rho GTPase Wrch1 collaborates with the nonreceptor
RT   tyrosine kinases Pyk2 and Src in regulating cytoskeletal dynamics.";
RL   Mol. Cell. Biol. 28:1802-1814(2008).
RN   [28]
RP   FUNCTION DURING LUNG INJURY, PHOSPHORYLATION BY MYLK, AND INTERACTION
RP   WITH MYLK.
RX   PubMed=18587400; DOI=10.1038/ni.1628;
RA   Xu J., Gao X.-P., Ramchandran R., Zhao Y.-Y., Vogel S.M., Malik A.B.;
RT   "Nonmuscle myosin light-chain kinase mediates neutrophil
RT   transmigration in sepsis-induced lung inflammation by activating beta2
RT   integrins.";
RL   Nat. Immunol. 9:880-886(2008).
RN   [29]
RP   FUNCTION IN REGULATION OF ACTIN CYTOSKELETON REORGANIZATION AND
RP   ACTIVATION OF RHO FAMILY GTPASES, PHOSPHORYLATION AT TYR-402,
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH VAV1.
RX   PubMed=19207108; DOI=10.1042/BJ20090037;
RA   Gao C., Blystone S.D.;
RT   "A Pyk2-Vav1 complex is recruited to beta3-adhesion sites to initiate
RT   Rho activation.";
RL   Biochem. J. 420:49-56(2009).
RN   [30]
RP   ROLE IN DISEASE, CATALYTIC ACTIVITY, AND ENZYME REGULATION.
RX   PubMed=19648005; DOI=10.1016/j.bmcl.2009.07.084;
RA   Allen J.G., Lee M.R., Han C.Y., Scherrer J., Flynn S., Boucher C.,
RA   Zhao H., O'Connor A.B., Roveto P., Bauer D., Graceffa R.,
RA   Richards W.G., Babij P.;
RT   "Identification of small molecule inhibitors of proline-rich tyrosine
RT   kinase 2 (Pyk2) with osteogenic activity in osteoblast cells.";
RL   Bioorg. Med. Chem. Lett. 19:4924-4928(2009).
RN   [31]
RP   FUNCTION IN CELL ADHESION AND SPREADING, AUTOPHOSPHORYLATION, AND
RP   INTERACTION WITH BCAR1.
RX   PubMed=19086031; DOI=10.1002/jcp.21649;
RA   Rufanova V.A., Alexanian A., Wakatsuki T., Lerner A., Sorokin A.;
RT   "Pyk2 mediates endothelin-1 signaling via p130Cas/BCAR3 cascade and
RT   regulates human glomerular mesangial cell adhesion and spreading.";
RL   J. Cell. Physiol. 219:45-56(2009).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-361; SER-375; SER-399;
RP   TYR-722; SER-762; TYR-819; TYR-834; SER-839; THR-842; TYR-849 AND
RP   SER-866, VARIANT [LARGE SCALE ANALYSIS] THR-838, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [33]
RP   FUNCTION IN IGF1 SIGNALING AND ACTIVATION OF MAPK1/ERK2 AND
RP   MAPK3/ERK1, INTERACTION WITH SRC AND GRB2, PHOSPHORYLATION AT TYR-402
RP   AND TYR-881, AND MUTAGENESIS OF TYR-881.
RX   PubMed=20521079; DOI=10.1007/s00018-010-0411-x;
RA   Shen X., Xi G., Radhakrishnan Y., Clemmons D.R.;
RT   "Recruitment of Pyk2 to SHPS-1 signaling complex is required for IGF-
RT   I-dependent mitogenic signaling in vascular smooth muscle cells.";
RL   Cell. Mol. Life Sci. 67:3893-3903(2010).
RN   [34]
RP   FUNCTION IN CELL PROLIFERATION AND REGULATION OF P53/TP53
RP   UBIQUITINATION, AND SUBCELLULAR LOCATION.
RX   PubMed=19880522; DOI=10.1074/jbc.M109.064212;
RA   Lim S.T., Miller N.L., Nam J.O., Chen X.L., Lim Y., Schlaepfer D.D.;
RT   "Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism
RT   facilitating cell proliferation and survival.";
RL   J. Biol. Chem. 285:1743-1753(2010).
RN   [35]
RP   PHOSPHORYLATION AT TYR-402 AND TYR-580 BY FYN AND LCK.
RX   PubMed=20028775; DOI=10.1189/jlb.0409227;
RA   Collins M., Tremblay M., Chapman N., Curtiss M., Rothman P.B.,
RA   Houtman J.C.;
RT   "The T cell receptor-mediated phosphorylation of Pyk2 tyrosines 402
RT   and 580 occurs via a distinct mechanism than other receptor systems.";
RL   J. Leukoc. Biol. 87:691-701(2010).
RN   [36]
RP   FUNCTION IN T-CELL RECEPTOR-MEDIATED SIGNALING, AND PHOSPHORYLATION AT
RP   TYR-402 AND TYR-580.
RX   PubMed=20381867; DOI=10.1016/j.molimm.2010.03.009;
RA   Collins M., Bartelt R.R., Houtman J.C.;
RT   "T cell receptor activation leads to two distinct phases of Pyk2
RT   activation and actin cytoskeletal rearrangement in human T cells.";
RL   Mol. Immunol. 47:1665-1674(2010).
RN   [37]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [38]
RP   INTERACTION WITH NPHP1, AND FUNCTION IN PHOSPHORYLATION OF NPHP1.
RX   PubMed=21357692; DOI=10.1074/jbc.M110.165464;
RA   Liebau M.C., Hopker K., Muller R.U., Schmedding I., Zank S.,
RA   Schairer B., Fabretti F., Hohne M., Bartram M.P., Dafinger C.,
RA   Hackl M., Burst V., Habbig S., Zentgraf H., Blaukat A., Walz G.,
RA   Benzing T., Schermer B.;
RT   "Nephrocystin-4 regulates Pyk2-induced tyrosine phosphorylation of
RT   nephrocystin-1 to control targeting to monocilia.";
RL   J. Biol. Chem. 286:14237-14245(2011).
RN   [39]
RP   FUNCTION IN REORGANIZATION OF CYTOSKELETON; FORMATION OF MEMBRANE
RP   RUFFLES AND CELL MIGRATION, AND ROLE IN DISEASE.
RX   PubMed=21533080; DOI=10.1371/journal.pone.0018878;
RA   Sun C.K., Ng K.T., Lim Z.X., Cheng Q., Lo C.M., Poon R.T., Man K.,
RA   Wong N., Fan S.T.;
RT   "Proline-rich tyrosine kinase 2 (Pyk2) promotes cell motility of
RT   hepatocellular carcinoma through induction of epithelial to
RT   mesenchymal transition.";
RL   PLoS ONE 6:E18878-E18878(2011).
RN   [40]
RP   REVIEW ON ROLE IN IMMUNITY.
RX   PubMed=15888917; DOI=10.1385/IR:31:3:267;
RA   Ostergaard H.L., Lysechko T.L.;
RT   "Focal adhesion kinase-related protein tyrosine kinase Pyk2 in T-cell
RT   activation and function.";
RL   Immunol. Res. 31:267-282(2005).
RN   [41]
RP   REVIEW ON FUNCTION; SIGNALING; INTERACTION PARTNERS; ENZYME
RP   REGULATION; PHOSPHORYLATION, AND ROLE IN DISEASE.
RX   PubMed=20001213; DOI=10.1517/14728220903473194;
RA   Lipinski C.A., Loftus J.C.;
RT   "Targeting Pyk2 for therapeutic intervention.";
RL   Expert Opin. Ther. Targets 14:95-108(2010).
RN   [42]
RP   REVIEW.
RX   PubMed=20332118; DOI=10.1242/jcs.045112;
RA   Schaller M.D.;
RT   "Cellular functions of FAK kinases: insight into molecular mechanisms
RT   and novel functions.";
RL   J. Cell Sci. 123:1007-1013(2010).
RN   [43]
RP   REVIEW ON ROLE IN DISEASE.
RX   PubMed=21196189; DOI=10.2741/3706;
RA   Felty Q.;
RT   "Redox sensitive Pyk2 as a target for therapeutics in breast cancer.";
RL   Front. Biosci. 16:568-577(2011).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-375 AND THR-842, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 416-692 IN COMPLEX WITH
RP   PF-2318841, CATALYTIC ACTIVITY, AND ENZYME REGULATION.
RX   PubMed=18951788; DOI=10.1016/j.bmcl.2008.10.030;
RA   Walker D.P., Bi F.C., Kalgutkar A.S., Bauman J.N., Zhao S.X.,
RA   Soglia J.R., Aspnes G.E., Kung D.W., Klug-McLeod J., Zawistoski M.P.,
RA   McGlynn M.A., Oliver R., Dunn M., Li J.C., Richter D.T., Cooper B.A.,
RA   Kath J.C., Hulford C.A., Autry C.L., Luzzio M.J., Ung E.J.,
RA   Roberts W.G., Bonnette P.C., Buckbinder L., Mistry A., Griffor M.C.,
RA   Han S., Guzman-Perez A.;
RT   "Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine
RT   kinase 2 (PYK2): structure-activity relationships and strategies for
RT   the elimination of reactive metabolite formation.";
RL   Bioorg. Med. Chem. Lett. 18:6071-6077(2008).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 861-1009 IN COMPLEX WITH PXN,
RP   AND INTERACTION WITH PXN.
RX   PubMed=19358827; DOI=10.1016/j.bbrc.2009.04.011;
RA   Lulo J., Yuzawa S., Schlessinger J.;
RT   "Crystal structures of free and ligand-bound focal adhesion targeting
RT   domain of Pyk2.";
RL   Biochem. Biophys. Res. Commun. 383:347-352(2009).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 416-692 IN COMPLEX WITH
RP   INHIBITOR P1E, ROLE IN DISEASE, CATALYTIC ACTIVITY, AND ENZYME
RP   REGULATION.
RX   PubMed=19428251; DOI=10.1016/j.bmcl.2009.04.093;
RA   Walker D.P., Zawistoski M.P., McGlynn M.A., Li J.C., Kung D.W.,
RA   Bonnette P.C., Baumann A., Buckbinder L., Houser J.A., Boer J.,
RA   Mistry A., Han S., Xing L., Guzman-Perez A.;
RT   "Sulfoximine-substituted trifluoromethylpyrimidine analogs as
RT   inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG
RT   activity.";
RL   Bioorg. Med. Chem. Lett. 19:3253-3258(2009).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 416-692 IN COMPLEXES WITH
RP   ATP ANALOG; PF-431396; BIRB796 AND PF-4618433, AND ROLE IN DISEASE.
RX   PubMed=19244237; DOI=10.1074/jbc.M809038200;
RA   Han S., Mistry A., Chang J.S., Cunningham D., Griffor M.,
RA   Bonnette P.C., Wang H., Chrunyk B.A., Aspnes G.E., Walker D.P.,
RA   Brosius A.D., Buckbinder L.;
RT   "Structural characterization of proline-rich tyrosine kinase 2 (PYK2)
RT   reveals a unique (DFG-out) conformation and enables inhibitor
RT   design.";
RL   J. Biol. Chem. 284:13193-13201(2009).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 414-692.
RG   Structural genomics consortium (SGC);
RT   "Structure of protein tyrosine kinase 2 beta (PTK2B) kinase domain.";
RL   Submitted (JUL-2011) to the PDB data bank.
RN   [50]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLU-359; HIS-698; PRO-808; THR-838 AND
RP   LYS-970.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Non-receptor protein-tyrosine kinase that regulates
CC       reorganization of the actin cytoskeleton, cell polarization, cell
CC       migration, adhesion, spreading and bone remodeling. Plays a role
CC       in the regulation of the humoral immune response, and is required
CC       for normal levels of marginal B-cells in the spleen and normal
CC       migration of splenic B-cells. Required for normal macrophage
CC       polarization and migration towards sites of inflammation.
CC       Regulates cytoskeleton rearrangement and cell spreading in T-
CC       cells, and contributes to the regulation of T-cell responses.
CC       Promotes osteoclastic bone resorption; this requires both
CC       PTK2B/PYK2 and SRC. May inhibit differentiation and activity of
CC       osteoprogenitor cells. Functions in signaling downstream of
CC       integrin and collagen receptors, immune receptors, G-protein
CC       coupled receptors (GPCR), cytokine, chemokine and growth factor
CC       receptors, and mediates responses to cellular stress. Forms
CC       multisubunit signaling complexes with SRC and SRC family members
CC       upon activation; this leads to the phosphorylation of additional
CC       tyrosine residues, creating binding sites for scaffold proteins,
CC       effectors and substrates. Regulates numerous signaling pathways.
CC       Promotes activation of phosphatidylinositol 3-kinase and of the
CC       AKT1 signaling cascade. Promotes activation of NOS3. Regulates
CC       production of the cellular messenger cGMP. Promotes activation of
CC       the MAP kinase signaling cascade, including activation of
CC       MAPK1/ERK2, MAPK3/ERK1 and MAPK8/JNK1. Promotes activation of Rho
CC       family GTPases, such as RHOA and RAC1. Recruits the ubiquitin
CC       ligase MDM2 to P53/TP53 in the nucleus, and thereby regulates
CC       P53/TP53 activity, P53/TP53 ubiquitination and proteasomal
CC       degradation. Acts as a scaffold, binding to both PDPK1 and SRC,
CC       thereby allowing SRC to phosphorylate PDPK1 at 'Tyr-9, 'Tyr-373',
CC       and 'Tyr-376'. Promotes phosphorylation of NMDA receptors by SRC
CC       family members, and thereby contributes to the regulation of NMDA
CC       receptor ion channel activity and intracellular Ca(2+) levels. May
CC       also regulate potassium ion transport by phosphorylation of
CC       potassium channel subunits. Phosphorylates SRC; this increases SRC
CC       kinase activity. Phosphorylates ASAP1, NPHP1, KCNA2 and SHC1.
CC       Promotes phosphorylation of ASAP2, RHOU and PXN; this requires
CC       both SRC and PTK2/PYK2. {ECO:0000269|PubMed:10022920,
CC       ECO:0000269|PubMed:12771146, ECO:0000269|PubMed:12893833,
CC       ECO:0000269|PubMed:14585963, ECO:0000269|PubMed:15050747,
CC       ECO:0000269|PubMed:15166227, ECO:0000269|PubMed:17634955,
CC       ECO:0000269|PubMed:18086875, ECO:0000269|PubMed:18339875,
CC       ECO:0000269|PubMed:18587400, ECO:0000269|PubMed:18765415,
CC       ECO:0000269|PubMed:19086031, ECO:0000269|PubMed:19207108,
CC       ECO:0000269|PubMed:19244237, ECO:0000269|PubMed:19428251,
CC       ECO:0000269|PubMed:19648005, ECO:0000269|PubMed:19880522,
CC       ECO:0000269|PubMed:20001213, ECO:0000269|PubMed:20381867,
CC       ECO:0000269|PubMed:20521079, ECO:0000269|PubMed:21357692,
CC       ECO:0000269|PubMed:21533080, ECO:0000269|PubMed:7544443,
CC       ECO:0000269|PubMed:8670418, ECO:0000269|PubMed:8849729}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:15050747,
CC       ECO:0000269|PubMed:15166227, ECO:0000269|PubMed:18339875,
CC       ECO:0000269|PubMed:18951788, ECO:0000269|PubMed:19428251,
CC       ECO:0000269|PubMed:19648005}.
CC   -!- ENZYME REGULATION: Activated in response to stimuli that lead to
CC       increased intracellular Ca(2+) levels; this activation is indirect
CC       and may be mediated by calcium-mediated production of reactive
CC       oxygen species (ROS). Activated by autophosphorylation at Tyr-402;
CC       this creates a binding site for SRC family kinases and leads to
CC       phosphorylation at additional tyrosine residues. Phosphorylation
CC       at Tyr-402, Tyr-579 and Tyr-580 is required for optimal kinase
CC       activity. Inhibited by PF-562,271, BIRB796, PF-4618433 and by PF-
CC       431396, PF-2318841 and their derivatives. Inhibited by
CC       sulfoximine-substituted trifluoromethylpyrimidines. Inhibited by
CC       4-amino and 5-aryl substituted pyridinone compounds.
CC       {ECO:0000269|PubMed:18339875, ECO:0000269|PubMed:18951788,
CC       ECO:0000269|PubMed:19428251, ECO:0000269|PubMed:19648005}.
CC   -!- SUBUNIT: Homodimer, or homooligomer. Interacts with SIRPA and
CC       SH2D3C. Interacts with ARHGAP10. Interacts with DLG4 (By
CC       similarity). Interacts with KCNA2 (By similarity). Interacts with
CC       NPHP1, ASAP1, ASAP2, ARHGAP26, SKAP2 and TGFB1I1. The Tyr-402
CC       phosphorylated form interacts with SRC (via SH2 domain) and SRC
CC       family members. Forms a signaling complex with EPHA1, LCK and
CC       phosphatidylinositol 3-kinase; upon activation by EFNA1. Interacts
CC       with GRB2 (via SH2 domain). Interacts with P53/TP53 and MDM2.
CC       Interacts with MYLK. Interacts with BCAR1. Interacts with PDPK1.
CC       Interacts (hypophosphorylated) with PXN. Interacts with RB1CC1.
CC       Interacts with RHOU. Interacts with VAV1. Interacts with LPXN and
CC       PTPN12. {ECO:0000250|UniProtKB:P70600,
CC       ECO:0000250|UniProtKB:Q9QVP9, ECO:0000269|PubMed:10022920,
CC       ECO:0000269|PubMed:10769033, ECO:0000269|PubMed:11493697,
CC       ECO:0000269|PubMed:12771146, ECO:0000269|PubMed:12893833,
CC       ECO:0000269|PubMed:14585963, ECO:0000269|PubMed:17329398,
CC       ECO:0000269|PubMed:17634955, ECO:0000269|PubMed:18086875,
CC       ECO:0000269|PubMed:18587400, ECO:0000269|PubMed:18765415,
CC       ECO:0000269|PubMed:18951788, ECO:0000269|PubMed:19086031,
CC       ECO:0000269|PubMed:19207108, ECO:0000269|PubMed:19358827,
CC       ECO:0000269|PubMed:19428251, ECO:0000269|PubMed:20521079,
CC       ECO:0000269|PubMed:21357692, ECO:0000269|PubMed:7544443,
CC       ECO:0000269|PubMed:8849729, ECO:0000269|PubMed:9422762}.
CC   -!- INTERACTION:
CC       O75161:NPHP4; NbExp=2; IntAct=EBI-298640, EBI-4281852;
CC       Q7L0Q8:RHOU; NbExp=4; IntAct=EBI-298640, EBI-1638043;
CC       P12931:SRC; NbExp=3; IntAct=EBI-298640, EBI-621482;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cytoplasm, perinuclear region.
CC       Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cell
CC       junction, focal adhesion. Cell projection, lamellipodium.
CC       Cytoplasm, cell cortex. Nucleus. Note=Interaction with NPHP1
CC       induces the membrane-association of the kinase. Colocalizes with
CC       integrins at the cell periphery.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q14289-1; Sequence=Displayed;
CC       Name=2; Synonyms=PYK2H;
CC         IsoId=Q14289-2; Sequence=VSP_004981;
CC   -!- TISSUE SPECIFICITY: Most abundant in the brain, with highest
CC       levels in amygdala and hippocampus. Low levels in kidney (at
CC       protein level). Also expressed in spleen and lymphocytes.
CC       {ECO:0000269|PubMed:7544443, ECO:0000269|PubMed:9545257}.
CC   -!- PTM: Phosphorylated on tyrosine residues in response to various
CC       stimuli that elevate the intracellular calcium concentration; this
CC       activation is indirect and may be mediated by production of
CC       reactive oxygen species (ROS). Tyr-402 is the major
CC       autophosphorylation site, but other kinases can also phosphorylate
CC       Tyr-402. Autophosphorylation occurs in trans, i.e. one subunit of
CC       the dimeric receptor phosphorylates tyrosine residues on the other
CC       subunit. Phosphorylation at Tyr-402 promotes interaction with SRC
CC       and SRC family members, leading to phosphorylation at Tyr-579;
CC       Tyr-580 and Tyr-881. Phosphorylation at Tyr-881 is important for
CC       interaction with GRB2. Phosphorylated on tyrosine residues upon
CC       activation of FGR and PKC. Recruitment by NPHP1 to cell matrix
CC       adhesions initiates Tyr-402 phosphorylation. In monocytes,
CC       adherence to substrata is required for tyrosine phosphorylation
CC       and kinase activation. Angiotensin II, thapsigargin and L-alpha-
CC       lysophosphatidic acid (LPA) also induce autophosphorylation and
CC       increase kinase activity. Phosphorylation by MYLK promotes ITGB2
CC       activation and is thus essential to trigger neutrophil
CC       transmigration during lung injury. Dephosphorylated by PTPN12.
CC       {ECO:0000269|PubMed:11493697, ECO:0000269|PubMed:15166227,
CC       ECO:0000269|PubMed:17329398, ECO:0000269|PubMed:18587400,
CC       ECO:0000269|PubMed:19207108, ECO:0000269|PubMed:20028775,
CC       ECO:0000269|PubMed:20381867, ECO:0000269|PubMed:20521079,
CC       ECO:0000269|PubMed:9545257}.
CC   -!- DISEASE: Note=Aberrant PTK2B/PYK2 expression may play a role in
CC       cancer cell proliferation, migration and invasion, in tumor
CC       formation and metastasis. Elevated PTK2B/PYK2 expression is seen
CC       in gliomas, hepatocellular carcinoma, lung cancer and breast
CC       cancer.
CC   -!- MISCELLANEOUS: Promotes bone resorption, and thus PTK2B/PYK2
CC       inhibitors might be used to treat osteoporosis.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. FAK subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U33284; AAC50203.1; -; mRNA.
DR   EMBL; L49207; AAB47217.1; -; mRNA.
DR   EMBL; D45853; BAA08289.1; -; mRNA.
DR   EMBL; U43522; AAC05330.1; -; mRNA.
DR   EMBL; S80542; AAB35701.1; -; mRNA.
DR   EMBL; AF311103; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471080; EAW63553.1; -; Genomic_DNA.
DR   EMBL; CH471080; EAW63555.1; -; Genomic_DNA.
DR   EMBL; CH471080; EAW63556.1; -; Genomic_DNA.
DR   EMBL; BC036651; AAH36651.1; -; mRNA.
DR   EMBL; BC042599; AAH42599.1; -; mRNA.
DR   CCDS; CCDS6057.1; -. [Q14289-1]
DR   CCDS; CCDS6058.1; -. [Q14289-2]
DR   PIR; S60248; S60248.
DR   RefSeq; NP_004094.3; NM_004103.4. [Q14289-1]
DR   RefSeq; NP_775266.1; NM_173174.2. [Q14289-1]
DR   RefSeq; NP_775267.1; NM_173175.2. [Q14289-2]
DR   RefSeq; NP_775268.1; NM_173176.2. [Q14289-1]
DR   RefSeq; XP_005273504.1; XM_005273447.4. [Q14289-1]
DR   RefSeq; XP_011542743.1; XM_011544441.2. [Q14289-1]
DR   RefSeq; XP_016868703.1; XM_017013214.1. [Q14289-1]
DR   UniGene; Hs.491322; -.
DR   UniGene; Hs.735450; -.
DR   PDB; 2FO6; Model; -; X=45-350.
DR   PDB; 2LK4; NMR; -; A=871-1005.
DR   PDB; 3CC6; X-ray; 1.60 A; A=414-692.
DR   PDB; 3ET7; X-ray; 2.70 A; A=416-692.
DR   PDB; 3FZO; X-ray; 2.20 A; A=416-692.
DR   PDB; 3FZP; X-ray; 2.10 A; A=416-692.
DR   PDB; 3FZR; X-ray; 2.70 A; A=416-692.
DR   PDB; 3FZS; X-ray; 1.75 A; A=416-692.
DR   PDB; 3FZT; X-ray; 1.95 A; A=416-692.
DR   PDB; 3GM1; X-ray; 2.95 A; A/B=861-1009.
DR   PDB; 3GM2; X-ray; 2.71 A; A=861-1009.
DR   PDB; 3GM3; X-ray; 2.60 A; A=861-1009.
DR   PDB; 3H3C; X-ray; 2.00 A; A=416-692.
DR   PDB; 3U3F; X-ray; 3.10 A; A/B/C/D=871-1005.
DR   PDB; 4EKU; X-ray; 3.25 A; A=21-409.
DR   PDB; 4H1J; X-ray; 2.00 A; A=416-692.
DR   PDB; 4H1M; X-ray; 1.99 A; A=416-692.
DR   PDB; 4R32; X-ray; 3.50 A; A=871-1005.
DR   PDB; 4XEF; X-ray; 2.50 A; A/D=871-1005.
DR   PDB; 4XEK; X-ray; 1.79 A; A=871-1005.
DR   PDB; 4XEV; X-ray; 2.01 A; A/D=871-1005.
DR   PDB; 5TO8; X-ray; 1.98 A; A=414-692.
DR   PDBsum; 2FO6; -.
DR   PDBsum; 2LK4; -.
DR   PDBsum; 3CC6; -.
DR   PDBsum; 3ET7; -.
DR   PDBsum; 3FZO; -.
DR   PDBsum; 3FZP; -.
DR   PDBsum; 3FZR; -.
DR   PDBsum; 3FZS; -.
DR   PDBsum; 3FZT; -.
DR   PDBsum; 3GM1; -.
DR   PDBsum; 3GM2; -.
DR   PDBsum; 3GM3; -.
DR   PDBsum; 3H3C; -.
DR   PDBsum; 3U3F; -.
DR   PDBsum; 4EKU; -.
DR   PDBsum; 4H1J; -.
DR   PDBsum; 4H1M; -.
DR   PDBsum; 4R32; -.
DR   PDBsum; 4XEF; -.
DR   PDBsum; 4XEK; -.
DR   PDBsum; 4XEV; -.
DR   PDBsum; 5TO8; -.
DR   ProteinModelPortal; Q14289; -.
DR   SMR; Q14289; -.
DR   BioGrid; 108480; 60.
DR   IntAct; Q14289; 15.
DR   MINT; MINT-1211326; -.
DR   STRING; 9606.ENSP00000332816; -.
DR   BindingDB; Q14289; -.
DR   ChEMBL; CHEMBL5469; -.
DR   DrugBank; DB01645; Genistein.
DR   DrugBank; DB01097; Leflunomide.
DR   GuidetoPHARMACOLOGY; 2181; -.
DR   iPTMnet; Q14289; -.
DR   PhosphoSitePlus; Q14289; -.
DR   BioMuta; PTK2B; -.
DR   DMDM; 3183003; -.
DR   EPD; Q14289; -.
DR   MaxQB; Q14289; -.
DR   PaxDb; Q14289; -.
DR   PeptideAtlas; Q14289; -.
DR   PRIDE; Q14289; -.
DR   TopDownProteomics; Q14289-2; -. [Q14289-2]
DR   DNASU; 2185; -.
DR   Ensembl; ENST00000346049; ENSP00000332816; ENSG00000120899. [Q14289-1]
DR   Ensembl; ENST00000397501; ENSP00000380638; ENSG00000120899. [Q14289-1]
DR   Ensembl; ENST00000420218; ENSP00000391995; ENSG00000120899. [Q14289-2]
DR   Ensembl; ENST00000517339; ENSP00000427931; ENSG00000120899. [Q14289-2]
DR   GeneID; 2185; -.
DR   KEGG; hsa:2185; -.
DR   UCSC; uc003xfn.3; human. [Q14289-1]
DR   CTD; 2185; -.
DR   DisGeNET; 2185; -.
DR   GeneCards; PTK2B; -.
DR   H-InvDB; HIX0168898; -.
DR   HGNC; HGNC:9612; PTK2B.
DR   HPA; CAB003850; -.
DR   HPA; HPA026091; -.
DR   HPA; HPA026276; -.
DR   MIM; 601212; gene.
DR   neXtProt; NX_Q14289; -.
DR   OpenTargets; ENSG00000120899; -.
DR   PharmGKB; PA33956; -.
DR   eggNOG; KOG4257; Eukaryota.
DR   eggNOG; ENOG410ZH9Y; LUCA.
DR   GeneTree; ENSGT00760000118799; -.
DR   HOGENOM; HOG000069938; -.
DR   HOVERGEN; HBG004018; -.
DR   InParanoid; Q14289; -.
DR   KO; K05871; -.
DR   OMA; VKTCKKD; -.
DR   OrthoDB; EOG091G03BN; -.
DR   PhylomeDB; Q14289; -.
DR   TreeFam; TF316643; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-391160; Signal regulatory protein (SIRP) family interactions.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-451927; Interleukin-2 signaling.
DR   SignaLink; Q14289; -.
DR   SIGNOR; Q14289; -.
DR   ChiTaRS; PTK2B; human.
DR   EvolutionaryTrace; Q14289; -.
DR   GeneWiki; PTK2B; -.
DR   GenomeRNAi; 2185; -.
DR   PRO; PR:Q14289; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000120899; -.
DR   CleanEx; HS_PTK2B; -.
DR   ExpressionAtlas; Q14289; baseline and differential.
DR   Genevisible; Q14289; HS.
DR   GO; GO:0097440; C:apical dendrite; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0044297; C:cell body; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0005938; C:cell cortex; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005856; C:cytoskeleton; IEA:InterPro.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0043197; C:dendritic spine; IEA:Ensembl.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0030426; C:growth cone; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0030027; C:lamellipodium; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0043025; C:neuronal cell body; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0017146; C:NMDA selective glutamate receptor complex; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0043423; F:3-phosphoinositide-dependent protein kinase binding; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004683; F:calmodulin-dependent protein kinase activity; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0004972; F:NMDA glutamate receptor activity; IEA:Ensembl.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0032403; F:protein complex binding; IEA:Ensembl.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:MGI.
DR   GO; GO:0005102; F:receptor binding; IBA:GO_Central.
DR   GO; GO:0004871; F:signal transducer activity; NAS:ProtInc.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IEA:Ensembl.
DR   GO; GO:0090630; P:activation of GTPase activity; IEA:Ensembl.
DR   GO; GO:0042976; P:activation of Janus kinase activity; IMP:UniProtKB.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0001525; P:angiogenesis; IBA:GO_Central.
DR   GO; GO:0006915; P:apoptotic process; TAS:ProtInc.
DR   GO; GO:0043534; P:blood vessel endothelial cell migration; IEA:Ensembl.
DR   GO; GO:0045453; P:bone resorption; ISS:UniProtKB.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0006968; P:cellular defense response; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0071498; P:cellular response to fluid shear stress; IEA:Ensembl.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IMP:BHF-UCL.
DR   GO; GO:0070098; P:chemokine-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0048041; P:focal adhesion assembly; IEA:Ensembl.
DR   GO; GO:0014009; P:glial cell proliferation; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0035235; P:ionotropic glutamate receptor signaling pathway; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0060292; P:long term synaptic depression; IEA:Ensembl.
DR   GO; GO:0060291; P:long-term synaptic potentiation; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0000165; P:MAPK cascade; IEA:Ensembl.
DR   GO; GO:0002315; P:marginal zone B cell differentiation; ISS:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0030502; P:negative regulation of bone mineralization; ISS:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0010656; P:negative regulation of muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0045638; P:negative regulation of myeloid cell differentiation; IMP:UniProtKB.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0043267; P:negative regulation of potassium ion transport; IDA:UniProtKB.
DR   GO; GO:0031175; P:neuron projection development; IEA:Ensembl.
DR   GO; GO:0001556; P:oocyte maturation; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IDA:BHF-UCL.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0030838; P:positive regulation of actin filament polymerization; IMP:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:2000538; P:positive regulation of B cell chemotaxis; ISS:UniProtKB.
DR   GO; GO:0030307; P:positive regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0001954; P:positive regulation of cell-matrix adhesion; IMP:UniProtKB.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IEA:Ensembl.
DR   GO; GO:2000573; P:positive regulation of DNA biosynthetic process; IEA:Ensembl.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IDA:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IMP:UniProtKB.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; IEA:Ensembl.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:BHF-UCL.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IEA:Ensembl.
DR   GO; GO:0051000; P:positive regulation of nitric-oxide synthase activity; IEA:Ensembl.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; ISS:UniProtKB.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; IMP:UniProtKB.
DR   GO; GO:2000060; P:positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IEA:Ensembl.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0045727; P:positive regulation of translation; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB.
DR   GO; GO:0006461; P:protein complex assembly; TAS:ProtInc.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:2000249; P:regulation of actin cytoskeleton reorganization; ISS:UniProtKB.
DR   GO; GO:0050848; P:regulation of calcium-mediated signaling; IEA:Ensembl.
DR   GO; GO:0030155; P:regulation of cell adhesion; IMP:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IMP:UniProtKB.
DR   GO; GO:0030826; P:regulation of cGMP biosynthetic process; IEA:Ensembl.
DR   GO; GO:0010752; P:regulation of cGMP-mediated signaling; IEA:Ensembl.
DR   GO; GO:2000114; P:regulation of establishment of cell polarity; ISS:UniProtKB.
DR   GO; GO:0032960; P:regulation of inositol trisphosphate biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0010758; P:regulation of macrophage chemotaxis; ISS:UniProtKB.
DR   GO; GO:2000310; P:regulation of NMDA receptor activity; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:2000058; P:regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0051279; P:regulation of release of sequestered calcium ion into cytosol; ISS:UniProtKB.
DR   GO; GO:0051592; P:response to calcium ion; IEA:Ensembl.
DR   GO; GO:0051591; P:response to cAMP; IEA:Ensembl.
DR   GO; GO:0042220; P:response to cocaine; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0009749; P:response to glucose; IEA:Ensembl.
DR   GO; GO:0009725; P:response to hormone; IEA:Ensembl.
DR   GO; GO:0042542; P:response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0035902; P:response to immobilization stress; IEA:Ensembl.
DR   GO; GO:0010226; P:response to lithium ion; IEA:Ensembl.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0006970; P:response to osmotic stress; IEA:Ensembl.
DR   GO; GO:0006950; P:response to stress; TAS:ProtInc.
DR   GO; GO:0007172; P:signal complex assembly; TAS:ProtInc.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0002040; P:sprouting angiogenesis; ISS:UniProtKB.
DR   GO; GO:0043149; P:stress fiber assembly; IEA:Ensembl.
DR   GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; IMP:BHF-UCL.
DR   Gene3D; 1.20.80.10; -; 1.
DR   InterPro; IPR019749; Band_41_domain.
DR   InterPro; IPR014352; FERM/acyl-CoA-bd_prot_3-hlx.
DR   InterPro; IPR019748; FERM_central.
DR   InterPro; IPR000299; FERM_domain.
DR   InterPro; IPR005189; Focal_adhesion_kin_target_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR011993; PH_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR030610; PTK2B.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR029071; Ubiquitin-rel_dom.
DR   PANTHER; PTHR24418:SF338; PTHR24418:SF338; 1.
DR   Pfam; PF00373; FERM_M; 1.
DR   Pfam; PF03623; Focal_AT; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   ProDom; PD006413; Focal_adhesion_target_reg; 1.
DR   SMART; SM00295; B41; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF47031; SSF47031; 1.
DR   SUPFAM; SSF50729; SSF50729; 1.
DR   SUPFAM; SSF54236; SSF54236; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF68993; SSF68993; 1.
DR   PROSITE; PS50057; FERM_3; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Alternative splicing; Angiogenesis;
KW   ATP-binding; Cell junction; Cell membrane; Cell projection;
KW   Complete proteome; Cytoplasm; Immunity; Kinase; Membrane;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Transferase; Tyrosine-protein kinase.
FT   CHAIN         1   1009       Protein-tyrosine kinase 2-beta.
FT                                /FTId=PRO_0000088081.
FT   DOMAIN       39    359       FERM. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00084}.
FT   DOMAIN      425    683       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     431    439       ATP.
FT   NP_BIND     503    509       ATP.
FT   REGION      801   1009       Interaction with TGFB1I1. {ECO:0000250}.
FT   REGION      868   1009       Focal adhesion targeting (FAT).
FT   COMPBIAS    702    767       Pro-rich.
FT   COMPBIAS    831    869       Pro-rich.
FT   ACT_SITE    549    549       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     457    457       ATP.
FT   MOD_RES     361    361       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     375    375       Phosphoserine.
FT                                {ECO:0000244|PubMed:18088087,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     399    399       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     402    402       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:11493697,
FT                                ECO:0000269|PubMed:15166227,
FT                                ECO:0000269|PubMed:17329398,
FT                                ECO:0000269|PubMed:19207108,
FT                                ECO:0000269|PubMed:20028775,
FT                                ECO:0000269|PubMed:20381867,
FT                                ECO:0000269|PubMed:20521079}.
FT   MOD_RES     579    579       Phosphotyrosine; by SRC, LYN and LCK.
FT                                {ECO:0000250}.
FT   MOD_RES     580    580       Phosphotyrosine; by SRC, LYN and LCK.
FT                                {ECO:0000269|PubMed:20028775,
FT                                ECO:0000269|PubMed:20381867}.
FT   MOD_RES     722    722       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     762    762       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     765    765       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     819    819       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     834    834       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     839    839       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195}.
FT   MOD_RES     842    842       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     849    849       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     866    866       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     881    881       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:20521079}.
FT   VAR_SEQ     739    780       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:9545257}.
FT                                /FTId=VSP_004981.
FT   VARIANT     359    359       Q -> E (in dbSNP:rs56175011).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041687.
FT   VARIANT     698    698       R -> H (in dbSNP:rs35174236).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041688.
FT   VARIANT     808    808       L -> P (in dbSNP:rs55747955).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041689.
FT   VARIANT     838    838       K -> T (in dbSNP:rs751019).
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_020284.
FT   VARIANT     970    970       E -> K (in dbSNP:rs56263944).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041690.
FT   MUTAGEN     402    402       Y->F: Abolishes autophosphorylation.
FT                                Abolishes interaction with SRC.
FT                                {ECO:0000269|PubMed:8849729}.
FT   MUTAGEN     457    457       K->A: Abolishes kinase activity.
FT                                {ECO:0000269|PubMed:15166227}.
FT   MUTAGEN     859    859       P->A: Loss of interaction with NPHP1.
FT                                {ECO:0000269|PubMed:11493697}.
FT   MUTAGEN     881    881       Y->F: Loss of phosphorylation site.
FT                                Strongly reduced interaction with GRB2.
FT                                {ECO:0000269|PubMed:20521079}.
FT   CONFLICT     23     23       A -> G (in Ref. 3; BAA08289/AAC05330).
FT                                {ECO:0000305}.
FT   CONFLICT    256    256       G -> P (in Ref. 2; AAB47217).
FT                                {ECO:0000305}.
FT   CONFLICT    435    435       F -> L (in Ref. 3; AAC05330).
FT                                {ECO:0000305}.
FT   CONFLICT    780    780       R -> G (in Ref. 2; AAB47217).
FT                                {ECO:0000305}.
FT   CONFLICT    985    985       V -> M (in Ref. 8; AAH36651).
FT                                {ECO:0000305}.
FT   HELIX        35     37       {ECO:0000244|PDB:4EKU}.
FT   STRAND       38     45       {ECO:0000244|PDB:4EKU}.
FT   STRAND       48     50       {ECO:0000244|PDB:4EKU}.
FT   HELIX        52     54       {ECO:0000244|PDB:4EKU}.
FT   STRAND       55     62       {ECO:0000244|PDB:4EKU}.
FT   HELIX        67     76       {ECO:0000244|PDB:4EKU}.
FT   TURN         77     80       {ECO:0000244|PDB:4EKU}.
FT   HELIX        87     89       {ECO:0000244|PDB:4EKU}.
FT   STRAND       90     99       {ECO:0000244|PDB:4EKU}.
FT   STRAND      102    105       {ECO:0000244|PDB:4EKU}.
FT   HELIX       111    117       {ECO:0000244|PDB:4EKU}.
FT   TURN        119    121       {ECO:0000244|PDB:4EKU}.
FT   HELIX       124    126       {ECO:0000244|PDB:4EKU}.
FT   STRAND      127    133       {ECO:0000244|PDB:4EKU}.
FT   TURN        138    140       {ECO:0000244|PDB:4EKU}.
FT   HELIX       141    144       {ECO:0000244|PDB:4EKU}.
FT   HELIX       148    165       {ECO:0000244|PDB:4EKU}.
FT   TURN        166    169       {ECO:0000244|PDB:4EKU}.
FT   HELIX       172    186       {ECO:0000244|PDB:4EKU}.
FT   TURN        187    189       {ECO:0000244|PDB:4EKU}.
FT   HELIX       194    196       {ECO:0000244|PDB:4EKU}.
FT   HELIX       198    207       {ECO:0000244|PDB:4EKU}.
FT   HELIX       210    212       {ECO:0000244|PDB:4EKU}.
FT   HELIX       216    221       {ECO:0000244|PDB:4EKU}.
FT   HELIX       224    238       {ECO:0000244|PDB:4EKU}.
FT   HELIX       243    254       {ECO:0000244|PDB:4EKU}.
FT   STRAND      263    273       {ECO:0000244|PDB:4EKU}.
FT   STRAND      277    282       {ECO:0000244|PDB:4EKU}.
FT   STRAND      285    289       {ECO:0000244|PDB:4EKU}.
FT   STRAND      297    300       {ECO:0000244|PDB:4EKU}.
FT   HELIX       302    304       {ECO:0000244|PDB:4EKU}.
FT   STRAND      310    313       {ECO:0000244|PDB:4EKU}.
FT   TURN        314    316       {ECO:0000244|PDB:4EKU}.
FT   STRAND      317    322       {ECO:0000244|PDB:4EKU}.
FT   STRAND      331    336       {ECO:0000244|PDB:4EKU}.
FT   HELIX       338    355       {ECO:0000244|PDB:4EKU}.
FT   STRAND      356    360       {ECO:0000244|PDB:4EKU}.
FT   HELIX       422    424       {ECO:0000244|PDB:3CC6}.
FT   STRAND      425    433       {ECO:0000244|PDB:3CC6}.
FT   STRAND      435    445       {ECO:0000244|PDB:3CC6}.
FT   STRAND      447    449       {ECO:0000244|PDB:3FZR}.
FT   STRAND      451    458       {ECO:0000244|PDB:3CC6}.
FT   STRAND      461    463       {ECO:0000244|PDB:3FZO}.
FT   HELIX       465    481       {ECO:0000244|PDB:3CC6}.
FT   STRAND      489    493       {ECO:0000244|PDB:3CC6}.
FT   STRAND      495    497       {ECO:0000244|PDB:3CC6}.
FT   STRAND      499    503       {ECO:0000244|PDB:3CC6}.
FT   HELIX       510    517       {ECO:0000244|PDB:3CC6}.
FT   TURN        518    520       {ECO:0000244|PDB:3CC6}.
FT   HELIX       523    542       {ECO:0000244|PDB:3CC6}.
FT   STRAND      546    548       {ECO:0000244|PDB:5TO8}.
FT   HELIX       552    554       {ECO:0000244|PDB:3CC6}.
FT   STRAND      555    559       {ECO:0000244|PDB:3CC6}.
FT   STRAND      562    565       {ECO:0000244|PDB:3CC6}.
FT   HELIX       570    572       {ECO:0000244|PDB:3CC6}.
FT   HELIX       589    591       {ECO:0000244|PDB:3CC6}.
FT   HELIX       594    599       {ECO:0000244|PDB:3CC6}.
FT   HELIX       604    619       {ECO:0000244|PDB:3CC6}.
FT   TURN        620    622       {ECO:0000244|PDB:3CC6}.
FT   TURN        625    628       {ECO:0000244|PDB:3CC6}.
FT   HELIX       631    633       {ECO:0000244|PDB:3CC6}.
FT   HELIX       634    640       {ECO:0000244|PDB:3CC6}.
FT   HELIX       652    661       {ECO:0000244|PDB:3CC6}.
FT   HELIX       666    668       {ECO:0000244|PDB:3CC6}.
FT   HELIX       672    691       {ECO:0000244|PDB:3CC6}.
FT   HELIX       879    897       {ECO:0000244|PDB:4XEK}.
FT   HELIX       898    900       {ECO:0000244|PDB:3GM3}.
FT   HELIX       903    905       {ECO:0000244|PDB:4XEK}.
FT   HELIX       906    927       {ECO:0000244|PDB:4XEK}.
FT   HELIX       928    930       {ECO:0000244|PDB:4XEK}.
FT   HELIX       933    962       {ECO:0000244|PDB:4XEK}.
FT   TURN        963    965       {ECO:0000244|PDB:4XEK}.
FT   HELIX       969   1004       {ECO:0000244|PDB:4XEK}.
SQ   SEQUENCE   1009 AA;  115875 MW;  420B21046274E7C2 CRC64;
     MSGVSEPLSR VKLGTLRRPE GPAEPMVVVP VDVEKEDVRI LKVCFYSNSF NPGKNFKLVK
     CTVQTEIREI ITSILLSGRI GPNIRLAECY GLRLKHMKSD EIHWLHPQMT VGEVQDKYEC
     LHVEAEWRYD LQIRYLPEDF MESLKEDRTT LLYFYQQLRN DYMQRYASKV SEGMALQLGC
     LELRRFFKDM PHNALDKKSN FELLEKEVGL DLFFPKQMQE NLKPKQFRKM IQQTFQQYAS
     LREEECVMKF FNTLAGFANI DQETYRCELI QGWNITVDLV IGPKGIRQLT SQDAKPTCLA
     EFKQIRSIRC LPLEEGQAVL QLGIEGAPQA LSIKTSSLAE AENMADLIDG YCRLQGEHQG
     SLIIHPRKDG EKRNSLPQIP MLNLEARRSH LSESCSIESD IYAEIPDETL RRPGGPQYGI
     AREDVVLNRI LGEGFFGEVY EGVYTNHKGE KINVAVKTCK KDCTLDNKEK FMSEAVIMKN
     LDHPHIVKLI GIIEEEPTWI IMELYPYGEL GHYLERNKNS LKVLTLVLYS LQICKAMAYL
     ESINCVHRDI AVRNILVASP ECVKLGDFGL SRYIEDEDYY KASVTRLPIK WMSPESINFR
     RFTTASDVWM FAVCMWEILS FGKQPFFWLE NKDVIGVLEK GDRLPKPDLC PPVLYTLMTR
     CWDYDPSDRP RFTELVCSLS DVYQMEKDIA MEQERNARYR TPKILEPTAF QEPPPKPSRP
     KYRPPPQTNL LAPKLQFQVP EGLCASSPTL TSPMEYPSPV NSLHTPPLHR HNVFKRHSMR
     EEDFIQPSSR EEAQQLWEAE KVKMRQILDK QQKQMVEDYQ WLRQEEKSLD PMVYMNDKSP
     LTPEKEVGYL EFTGPPQKPP RLGAQSIQPT ANLDRTDDLV YLNVMELVRA VLELKNELCQ
     LPPEGYVVVV KNVGLTLRKL IGSVDDLLPS LPSSSRTEIE GTQKLLNKDL AELINKMRLA
     QQNAVTSLSE ECKRQMLTAS HTLAVDAKNL LDAVDQAKVL ANLAHPPAE
//
